

## Bod Science Aqua Phase CBD PK results demonstrates 6 times greater bioavailability.

- Aqua Phase CBD PK results demonstrates 6 times greater bioavailability than CBD in oil. This completes Bod's research and development work to support the commercialisation of the Aqua Phase technology.
- Outcomes support the commercial opportunities of the technology as a preferred oral dose format, solving solubility and bioavailability limitations of water hating molecules.
- Results have demonstrated multiple benefits of the Aqua Phase Complex compared to CBD in Oil<sup>1</sup>

**Sydney, Australia – 27 September 2023:** Cannabis focused drug development and product innovation company Bod Science Limited (“Bod” or “the Company”) (ASX: BOD) today announces a further update on the development work to support the commercialisation of the Aqua Phase technology, with the CBD PK study investigating the bioavailability in venous blood results demonstrating 6 times greater bioavailability. The research and development work completed supports the commercialisation of the Aqua Phase technology solution as a preferred oral dose format.

Bod has now completed two PK studies to demonstrate the enhanced bioavailability of CBD complexed with the Aqua Phase technology compared with CBD in MCT oil. The initial PK Study completed in July 2023<sup>2</sup> assessed bioavailability in capillary blood. Data from Bod's two PK studies demonstrated consistent results, although significantly increased bioavailability was seen for the venous study.

This, the final CBD PK study, was a Phase 1 study investigating the bioavailability in venous blood which enrolled 12 healthy volunteers who were dosed with either Aqua Phase CBD 100mg or CBD 100mg in oil. The trial was conducted under strict research conditions where dosing and sampling conditions were highly controlled, participants were fasted, and the trial was an ethics approved study and conducted at a site experienced with pharmacokinetic studies.

The final results have demonstrated the multiple benefits of the Aqua Phase CBD compared to CBD in Oil<sup>1</sup> including;

1. **AUC** (AUC = Measure of absorption/bioavailability)
  - **Results:** Aqua Phase CBD was more than 530% (6.3 times) greater than CBD in oil
  - **Benefit:** Aqua Phase CBD showed longer exposure of CBD in blood for greater potential effect
  - **Commercial opportunity:** Confirms the utility of Aqua Phase to help solve absorption and bioavailability issues for lipophilic molecules
2. **C<sub>max</sub>** (C<sub>max</sub>= The maximum concentration achieved)
  - **Results:** Aqua Phase CBD achieved approximately 270% (3.7 times) greater maximum concentration (C<sub>max</sub>) than CBD in oil
  - **Benefit:** Higher concentrations of the dose in the body to address clinical needs
  - **Commercial opportunity:** Opens up a dosing benefit that can be leverage to reduce the amount of active ingredient required, minimising cost of development and potential side effects of drugs
3. **T<sub>max</sub>** (T<sub>max</sub> = speed of onset and shows the time taken for the CBD dose to reach maximum concentration)
  - **Results:** Aqua Phase CBD reaches its maximum concentration in 2.5 hrs vs 6 hrs for CBD in oil
  - **Benefit:** Aqua Phase achieves higher exposure much earlier than oil, giving a faster acting product
  - **Commercial opportunity:** This is an attractive attribute for development of CBD for conditions where a quick onset is important

<sup>1</sup> Two-way randomised crossover study on 12 healthy individuals receiving 100mg CBD Aqua Phase CBD and CBD in MCT oil.

<sup>2</sup> ASX release 25 July 2023 Completion of Pivotal Aqua Phase PK Studies

**Management commentary:**

**CEO Ms Jo Patterson said:** *“We are pleased with the results from this second PK study as they further support the exciting properties of Aqua Phase as a unique product delivery process technology. The results verify the value proposition.*

*Aqua Phase holds a broader opportunity for drugs that have solubility and bioavailability limitation, not being limited to the cannabis sector. We are excited with the outcome of the this PK study, as it is another milestone in our work to unlock these commercial opportunities of Aqua Phase for our shareholders.”*

Aqua Phase is a product delivery process technology that solves solubility and bioavailability limitations with drugs that are poorly absorbed by the body through oral dose formats. Importantly, compounds complexed with Aqua Phase present both as soluble and stable in aqueous solutions. Whilst Aqua Phase has significant application within the cannabis sector it is agnostic in its application and offers a much broader opportunity. The commercial roll out holds opportunity for applications across cannabis, pharmaceutical, nutraceuticals and beverage markets.

**This announcement has been approved by the Board of Bod Science Limited.**

**-ENDS-**

**About Bod Science:**

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
Info@bodaustralia.com  
+61 2 9199 5018

Amalie Schreurs  
White Noise Communications  
amalie@whitenoisecomms.com  
+61 431 636 033